Endogard Plus Flavour (10 kg)

10 x 10 pc

Tablet

Active substance

Febantel : 150 mg

Pyrantel (Pyrantel embonat) : 144 mg

Praziquantel : 50 mg

ATC code

QP52AC55 Febantel, comb.

QP52AC Benzimidazoles and related substances

QP52A Anthelmintics

QP52 Anthelmintics

QP Antiparasitic products, insecticides and repellents

Species

Dogs (small and medium size).

Indications

For the treatment of mixed infections with the following roundworms and tapeworms in adult dogs and puppies:

Nematodes

Ascarids: Toxocara canis, Toxascaris leonina (late immature forms and mature forms)

Hookworms: Uncinaria stenocephala, Ancylostoma caninum (adults)

Cestodes

Tapeworms: Taenia spp., Dipylidium caninum

Dose to be administered and administration route

For oral administration.

Dosage

The recommended dose rates are: 15 mg/kg bodyweight febantel, 14.4 mg/kg pyrantel and 5 mg/kg praziquantel. This is equivalent to 1 tablet per 10 kg bodyweight.

Tablets may be halved/quartered to allow accuracy of dosing.

Administration and Duration of Treatment

The tablet(s) can be given directly to the dog or disguised in food. No restriction of access to food is required either before or after administration of the product. To ensure a correct dosage, body weight should be determined as accurately as possible.

Puppies may be wormed with this product from 2 weeks of age and every 2 weeks until 12 weeks of age. Thereafter they should be treated at 3 monthly intervals. It is advisable to treat the bitch at the same time as the puppies.

For the control of Toxocara, nursing bitches should be dosed 2 weeks after giving birth and every 2 weeks until weaning.

For routine control a single dose is recommended at 3 monthly intervals.

In the event of a heavy roundworm infestation, a repeat dose should be given after 14 days.

Adverse reactions

Dogs:

Rare

(1 to 10 animals / 10,000 animals treated):

Loose stool^¹, diarrhoea^1,², vomiting^1,2

¹ In puppies: transient.

² In adult dogs: very rare cases of vomiting, with or without diarrhoea.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for contact details.